Nalbuphine

Nalbuphine is a semi-synthetic opioid analgesic that operates through a distinctive pharmacological mechanism, serving as both an agonist and antagonist of opioid receptors. Specifically, Nalbuphine activates kappa opioid receptors while concurrently blocking mu opioid receptors. This unique receptor profile enables Nalbuphine to provide effective analgesia while minimising the risk of severe respiratory depression commonly associated with traditional opioids such as morphine. Due to this favourable safety profile, Nalbuphine is extensively utilised in clinical practice, particularly within surgical and emergency medicine. Classified as a Schedule II controlled substance, Nalbuphine demonstrates a relatively lower potential for misuse, making it an attractive choice in settings requiring dependable pain control.

Image source Google

Fortwin Injection

 

Pentazocine: A Scholarly Review

Pentazocine, a synthetic benzomorphan opioid, serves as a pivotal agent in the management of moderate to severe pain. Its pharmacological uniqueness lies in its dual agonist-antagonist activity, predominantly acting on kappa-opioid receptors while exhibiting partial antagonism at mu-opioid receptors. This confers a distinctive analgesic profile, with implications for both efficacy and safety in clinical practice.

image source Google